The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?
Keyword(s):
2020 ◽
Keyword(s):
2015 ◽
Vol 16
(10)
◽
pp. 899.e1-899.e7
◽
Keyword(s):
2018 ◽
Vol Volume 13
◽
pp. 2397-2406
◽